Founding a Health Impact Startup: What Data Investors Expect from Day One

The Gap Between Health Tech and Health Impact

Digital health venture funding reached $10.7 billion in 2023, according to Rock Health's Annual Digital Health Funding Report. The overwhelming majority flows to startups building tools for the commercially insured, the smartphone-native, and the urban professional. These are health technology companies. They are not, by most rigorous definitions, health impact companies.

The distinction matters increasingly as the global impact investing market, now at $1.571 trillion in assets under management (GIIN, 2024), applies more rigorous scrutiny to what qualifies as impact. A founder building for federally qualified health centers serving Medicaid populations is operating in a fundamentally different investability framework than a founder building a premium wellness app.

Outcome Measurement Is Not Optional — and It Cannot Start Later

The most common structural mistake health founders make when approaching impact capital is treating outcome measurement as a future problem. Impact investors see it differently. The data architecture you build in the first eighteen months becomes the evidentiary foundation on which all future diligence rests.

The industry standard for impact measurement in health is the IRIS+ framework maintained by the GIIN. Impact investors expect founders to be familiar with this framework and to have a baseline dataset demonstrating active measurement. Specific metrics investors scrutinize include: the percentage of patients below 200% of the federal poverty line, disaggregated health outcome data by race and ethnicity, and cost-per-outcome relative to the standard of care.

Regulatory Pathway as Investment Signal

Healthcare operates under a regulatory architecture that most other industries do not. The FDA's Digital Health Center of Excellence has issued clearance for over 1,000 AI/ML-enabled devices as of 2024. For health founders building clinical-grade software or AI-enabled diagnostics, the question is whether the founder understands which pathway applies and how regulatory risk has been priced into the financial model.

Tools designed for safety-net providers — rural hospitals, community health centers, tribal health programs — operate under different reimbursement structures and compliance requirements. The founder who has mapped these requirements and engaged FDA pre-submission is communicating operational maturity that is weighted heavily in health impact diligence.

Unit Economics in Underserved Markets

The structural tension in health impact investing is that the populations most in need of healthcare innovation are the least commercially attractive under conventional SaaS economics. Medicaid reimbursement rates run 30–40% below Medicare. A founder building for impact must build unit economics that work at lower average contract values.

Impact investors require founders to have solved for these constraints. The diligence questions include: What is the fully-loaded cost to serve a single patient? What is your reimbursement pathway? How does your gross margin profile change from pilot to scale? A founder who cannot answer with specificity is communicating that they have not stress-tested their model against the economics of the market they claim to serve.

Clinical Evidence: The Bar Has Moved

The digital health industry spent much of the 2010s operating on the assumption that clinical evidence could follow commercial traction. That assumption has not survived institutional scrutiny. The FDA's 2024 predetermined change control plan guidance formalized the expectation that AI/ML-based devices demonstrate ongoing real-world performance.

For health impact founders, the clinical evidence bar is higher, not lower. Impact investors must be able to defend the claim that the product produces measurable positive outcomes. This does not require a full randomized controlled trial at seed stage. It does require a rigorous observational design with pre-specified primary outcomes and enough preliminary data to demonstrate the clinical hypothesis is testable.

How Impact Investors Evaluate Health Ventures Differently

Traditional venture capital evaluates health startups primarily on market size, team credentials, and product differentiation. Impact investors overlay a second evaluation: additionality — whether the outcome would have occurred without the investment. A platform routing uninsured patients to community health services produces measurable additionality in a way that commercially insured telehealth does not.

88% of impact investors meet or exceed their financial return expectations (GIIN). For health founders, the implication is that impact investors are rigorous capital allocators who require both a credible path to financial returns and a defensible impact thesis. The $124 trillion wealth transfer projected through 2048 (Cerulli Associates, December 2024) will deploy significant capital into health impact, but it will flow to founders who have built infrastructure to absorb institutional scrutiny.

The Ivystone Perspective: Building Investable Data Infrastructure from the Start

At Ivystone, we work with health founders at the earliest stages because the decisions made in the first twelve to eighteen months determine whether the company will ever be fundable by serious impact capital. The most common pattern we observe is not a failure of mission. It is a failure of data architecture — founders arriving at capital conversations without disaggregated outcome data, mapped regulatory pathways, or unit economics benchmarked against Medicaid reimbursement.

Our advisory work focuses on a single principle: build the data infrastructure that satisfies both clinical and financial due diligence simultaneously, from day one. This means establishing patient outcome measurement protocols before the first clinical pilot, engaging a regulatory strategist before the product roadmap is locked, and mapping your impact thesis to IRIS+ before the first investor conversation. Health impact investing is one of the most consequential applications of private capital available. The founders who reach institutional capital are those who treated investability as a design constraint from the start.